Preis E, Albers P, Jakse G
Urologische Klinik, Universitätsklinikum RWTH, Aachen, Germany.
Urologe A. 2006 May;45(5):609-13. doi: 10.1007/s00120-006-1046-2.
Penile cancer is a rare tumor in Europe with an incidence of 0.1-0.9 per 100,000 men per year. The success of our therapy is mainly influenced by the presence of lymph node metastases. At first diagnosis 17-45% of patients already harbor lymph node metastases. Bilateral inguinal and pelvic lymphadenectomy is a curative measure in these patients. In cases of gross inguinal metastases neoadjuvant chemotherapy leads to a remission rate of 21-60% and improves the resectability. The influence on survival is not proven. The same holds true for adjuvant therapy following lymphadenectomy. Polychemotherapy rarely leads to long-lasting complete remission in patients with distant metastases. The protocols consist usually of cisplatin, bleomycin, methotrexate, and 5-fluorouracil. The overall remission rate is around 15-32%. Because of the low efficacy of the present chemotherapy regimens, one should follow new strategies, comparable to those initiated for squamous cell cancer of other organs.
阴茎癌在欧洲是一种罕见肿瘤，每年每10万名男性中的发病率为0.1 - 0.9。我们治疗的成功主要受淋巴结转移情况的影响。初诊时，17% - 45%的患者已存在淋巴结转移。双侧腹股沟和盆腔淋巴结清扫术是这些患者的一种治愈性措施。在存在明显腹股沟转移的病例中，新辅助化疗可使缓解率达到21% - 60%，并提高可切除性。对生存率的影响尚未得到证实。淋巴结清扫术后的辅助治疗情况也是如此。多药化疗很少能使有远处转移的患者实现长期完全缓解。治疗方案通常由顺铂、博来霉素、甲氨蝶呤和5 - 氟尿嘧啶组成。总体缓解率约为15% - 32%。鉴于目前化疗方案疗效较低，应采用新的策略，类似于针对其他器官鳞状细胞癌所启动的策略。
